Oncology News

A novel evaluation of biomarkers known to be associated with pancreatic cancer significantly improved detection of early-stage disease compared with previous tests, according to results of a double-blind phase 2 trial.

PHILADELPHIA— AI-assisted-colonoscopy significantly increased the number of colonoscopy procedures in which only benign lesions were removed without additional adenomatous polyps, according to data at the ACG Annual Scientific Meeting.

Both colonoscopies and stool-based tests for colorectal cancer screening may be more efficient and cost-effective compared with blood-based tests, study findings published in Annals of Internal Medicine showed.

The delivery of transvascular energy reduced pain and improved quality of life within 7 days among patients with pancreatic cancer, according to a topline data announcement.

PHILADELPHIA—An AI-assisted endoscopy module minorly improved adenoma detection during colonoscopy, but “had no impact” on serrated polyp detection in patients with positive stool tests, a presenter said at the ACG Annual Scientific Meeting.

PHILADELPHIA — Patients with a false-positive Shield test result did not appear to be at increased risk for non-colorectal cancer malignancies at 1 year compared with those with a true-negative result, according to a presenter here.

PHILADELPHIA — Patients with type 2 diabetes on glucagon-like peptide-1 receptor agonists had significantly lower risk for pancreatic cancer compared with those on other antidiabetic therapies, regardless of weight, according to data.

PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.

Individuals with no detectable hemoglobin in previously negative fecal immunochemical tests had a “significantly higher” harm-to-benefit ratio for screening, with researchers suggesting less intensive screening for this population.